Workflow
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics
BLCOBausch + Lomb (BLCO) ZACKS·2025-02-17 15:21

Core Insights - Bausch + Lomb (BLCO) is expected to report quarterly earnings of 0.24pershare,indicatingnochangefromthepreviousyear,withrevenuesforecastedat0.24 per share, indicating no change from the previous year, with revenues forecasted at 1.27 billion, reflecting a 7.9% year-over-year increase [1] Earnings Estimates - The consensus EPS estimate has been revised 5.8% lower over the last 30 days, indicating a reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts predict 'Revenue- Vision Care' at 708.34million,suggestinga7708.34 million, suggesting a 7% year-over-year increase [5] - 'Revenue- Pharmaceuticals' is estimated to be 335.50 million, indicating a 9.3% year-over-year increase [5] - 'Revenue- Product sales' is expected to reach 1.26billion,reflectinga7.71.26 billion, reflecting a 7.7% year-over-year increase [5] - 'Revenue- Surgical' is forecasted at 215.26 million, indicating a 5.5% increase from the prior year [6] - 'Revenue- Other' is projected to be $5.00 million [6] Stock Performance - Bausch + Lomb shares have shown a return of -5.5% over the past month, contrasting with the Zacks S&P 500 composite's +4.7% change, indicating underperformance [7] - The company holds a Zacks Rank 4 (Sell), suggesting it is expected to lag the overall market performance in the near future [7]